Short answer
PRECIGEN, INC. (PGEN) filed an 8-K current report with the SEC on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 contains Precigen’s financial results for the quarter ended June 30, 2026.
PRECIGEN, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Exhibit 99.1 contains Precigen’s financial results for the quarter ended June 30, 2026
- August 4, 2026 press release provides the substantive earnings details
- Disclosure furnished under Item 2.02, not deemed filed under Section 18 or incorporated by reference
Item EX-99.1 · Exhibit EX-99.1
- PAPZIMEOS revenue reached $53.1 million in Q2, more than doubling from the prior quarter and driving quarterly net income of $20.1 million
- Total revenue rose to $55.0 million from $0.9 million, while operating income reached $22.6 million versus a $31.8 million loss
- Cash, equivalents, and investments totaled $38.7 million at June 30, with management targeting cash-flow break-even by year-end 2026
- FDA granted PAPZIMEOS seven-year market exclusivity, strengthening commercial protection against prospective competition
- Broad adoption supported by over 500 hub-enrolled patients, coverage across approximately 315 million US lives, and permanent J-code J3404
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PRECIGEN, INC. 8-K filings
Get the next PGEN 8-K as it lands
Follow PGEN for push alerts, or ask the research agent what this filing means.